Core Insights - Hoth Therapeutics, Inc. is set to present advancements in its clinical pipeline, specifically focusing on HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors [1][5] - The presentation will take place at the BIO-Europe 2025 Conference in Vienna, Austria, from November 3–5, 2025, highlighting the company's commitment to developing breakthrough therapies for patients with high unmet needs [2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments aimed at improving patient quality of life, with a focus on dermatological, oncology, and Alzheimer's therapeutics [3] - The company employs a patient-centric approach, collaborating with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [3] Development Programs - HT-001 is designed as a topical therapeutic to reduce rash and skin toxicity associated with cancer therapies, including EGFR inhibitors and radiotherapy [5] - HT-KIT is a precision oncology program that targets cancers driven by dysregulated KIT signaling [5]